🇺🇸 FDA
Patent

US 9359418

Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use

granted A61KA61K38/00A61P

Quick answer

US patent 9359418 (Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/00, A61P, A61P1/18, A61P19/02